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The heart has no measurable potential to synthesize FA, and thus is dependent upon exogenous supply, a process that is accelerated by transporters like FA transport protein, CD36, and FA-binding protein plasma membrane (24) . Exogenous sources of FA include the plasma free FA fraction or FA released during hydrolysis of triglyceride (TG)-rich lipoproteins; the latter is considered to be the principal source of FA for cardiac utilization (2, 41) . Lipoprotein lipase (LPL) is the rate-limiting enzyme for lipoprotein TG breakdown. LPL synthesized in cardiomyocytes is secreted as an active enzyme and binds to myocyte cell surface heparan sulfate proteoglycans (HSPG). Subsequently, the enzyme is translocated to comparable HSPG binding sites on the luminal side of the vessel wall where TG lipolysis occurs (6, 7, 38, 39) .
The "fuel gauge" AMP-activated protein kinase (AMPK) regulates cellular metabolism (15) . During metabolic stresses associated with energy depletion, like ischemia (when manufacture of ATP is hindered) or exercise (when ATP expenditure is augmented), changes in intracellular AMP/ATP levels promote threonine (Thr 172 ) phosphorylation and activation of AMPK, an important regulator of both lipid and carbohydrate metabolism (14, 17) . Once stimulated, AMPK switches off energy-consuming processes like TG and protein synthesis, whereas ATP-generating mechanisms are turned on. Thus, in heart and skeletal muscle, phosphorylated AMPK stimulates glucose uptake by inducing GLUT4 recruitment to the plasma membrane (16, 21, 35) and subsequent glycolysis through activation of 6-phosphofructo-2-kinase (25) . More importantly, through its control of ACC, AMPK facilitates FA utilization. As ACC catalyzes the conversion of acetyl-CoA to malonyl-CoA, AMPK, by inhibiting ACC, is able to decrease malonyl-CoA and minimize its inhibition of FA oxidation (19, 20) .
The majority of studies examining AMPK regulation of FA utilization have focused on FA oxidation. More recently, AMPK has also been implicated in FA delivery to cardiomyocytes through its regulation of CD36 (23) . Given the importance of LPL in providing hearts with FA (2, 41) , the objective of the present study was to investigate whether activation of AMPK influences LPL at its functionally relevant location, the coronary lumen. We demonstrate that, after AMPK phosphorylation, heparin-releasable LPL activity is amplified, providing an additional mechanism whereby this metabolic "switch" could regulate cellular energy.
MATERIALS AND METHODS
Experimental animals. The investigation conforms to the Guide for the Care and Use of Laboratory Animals published by the United States National Institutes of Health and the University of British Columbia (UBC). Adult male Wistar rats (220 -240 g) were obtained from the UBC Animal Care Unit and were supplied with a standard laboratory diet (PMI Feeds, Richmond, VA) and water ad libitum. Where indicated, some rats were fasted for 16 h (6:00 PM to 10:00 AM). During fasting, food was withdrawn from the animals, but they had free access to water.
Isolated heart perfusion. Hearts were isolated and perfused as described previously (32) . Briefly, rats were anesthetized with 65 mg/kg pentobarbital sodium, and the hearts were carefully excised. Rats were not injected with heparin before killing because it displaces LPL bound to HSPG on the capillary endothelium. Consequently, it was necessary to cannulate the heart quickly to avoid clotting of blood in the coronary arteries. After cannulation of the aorta, hearts were secured by tying below the innominate artery and perfused retrogradely with Krebs-Henseleit HEPES buffer containing 10 mM glucose (pH 7.4). Perfusion fluid was continuously gassed with 95% O 2-5% CO2. The rate of coronary flow (7-8 ml/min) was controlled by a peristaltic pump.
Coronary lumen LPL activity. To measure coronary endotheliumbound LPL, the perfusion solution was changed to buffer containing 1% FA-free BSA and heparin (5 U/ml). This concentration of heparin can maximally release cardiac LPL from its HSPG binding sites. The coronary effluent (perfusate that drips down to the apex of the heart) was collected in timed fractions (10 s) over 5 or 10 min where indicated and assayed for LPL activity by measuring the hydrolysis of a sonicated [ 3 H]triolein substrate emulsion (34) . Retrograde perfusion of whole hearts with heparin results in a discharge of LPL that is rapid (within 0.5-1 min; suggested to represent LPL located at or near the endothelial cell surface) followed by a prolonged slow release (that is considered to originate from the myocyte cell surface; see Ref. 32 ). Because we were primarily concerned with examining AMPK regulation of LPL at the coronary lumen, only peak LPL activities are shown. LPL activity is expressed as nanomoles oleate released per hour per milliliter. Subsequent to LPL displacement with heparin, hearts were removed rapidly, washed with Krebs buffer, frozen in liquid nitrogen, and stored at Ϫ80°C for Western blot assay of AMPK.
Western blotting for AMPK. AMPK phosphorylation increases its activity ϳ50-to 100-fold. To determine total and phosphorylated AMPK-␣, whole cell homogenates were isolated as described previously (1) . Briefly, hearts were ground under liquid nitrogen and 50 mg were homogenized. After centrifugation at 5,000 g for 20 min, the protein content of the supernatant was quantified using a Bradford protein assay. Samples were diluted and boiled with sample loading dye, and 50 g were used in SDS-PAGE. After transfer, membranes were blocked in 5% skim milk in Tris-buffered saline containing 0.1% Tween 20. Membranes were incubated either with rabbit AMPK-␣ or phosopho-AMPK (Thr 172 ) antibody, and subsequently with secondary goat anti-rabbit horseradish peroxidase (HRP)-conjugated antibody, and visualized using an ECL detection kit. Measurement of cardiac LPL expression. LPL gene expression was measured in the indicated groups using RT-PCR. Briefly, total RNA from hearts (100 mg) was extracted using Tri-Zol (Invitrogen). After spectrophotometric quantification and resolving of RNA integrity using a formaldehyde agarose gel, reverse transcription was carried out using an oligo(dT) primer and superscript II RT (Invitrogen). cDNA was amplified using LPL-specific primers (8) [5Ј-ATC-CAGCTGGGCCTAACTTT-3Ј (left) and 5Ј-AATGGCTTCTCCAA-TGTTGC-3Ј (right)]. The ␤-actin gene was amplified as an internal control using 5Ј-TGGTGGGTATGGGTCAGAAGG-3Ј (left) and 5Ј-ATCCTGTCAGCGATGCCTGGG-3Ј (right). The linear range was found to be between 15 and 30 cycles. The amplification parameters were set at 94°C for 1 min, 58°C for 1 min, and 72°C for 1 min for a total of 30 cycles. The PCR products were electrophoresed on a 1.7% agarose gel containing ethidium bromide. Expression levels were represented as the ratio of signal intensity for LPL mRNA relative to ␤-actin mRNA.
Measurement of LPL protein and activity in cardiomyocytes. Because endothelial cells cannot synthesize LPL, it is manufactured and processed in myocytes and then translocated across the interstitial space on HSPG-binding sites on the luminal surface of endothelial cells (38, 39) . LPL protein and activity measurement was done using isolated cardiomyocytes. Ventricular calcium-tolerant myocytes were prepared by a previously described procedure (29, 30) . Cardiac myocytes were suspended at a final cell density of 0.4 ϫ 10 6 cells/ml, medium was separated by centrifugation, and LPL protein and activity were assayed in cell pellets.
For Western blot analysis, 25 g of total protein were size fractionated in a SDS-polyacrylamide gel and blotted on a nitrocellulose membrane. After being blocked overnight at 4°C, the membrane was transferred to a solution of 1:1,000 diluted primary antibody (5D2, a monoclonal mouse anti-bovine LPL generously provided by Dr. J. Brunzell, University of Washington, Seattle, WA) and kept for 2 h at room temperature with gentle shaking. After being washed with TBS-Tween 20, the membrane was treated with 1:3,000 diluted secondary antibody (sheep anti-mouse IgG HRP conjugated) for 1 h at room temperature and visualized using an ECL detection kit. Measurement of LPL activity in the cell pellet was carried out by a previously described method (32) .
Immunolocalization of LPL. Hearts were removed and placed in 10% formalin for 24 h. After formalin fixation and paraffin embedding, 3-m sections were cut on silane-coated glass slides. Immunostaining was carried out as described before (30) . Briefly, after deparaffinization and rehydration, slides were treated with 5% (vol/ vol) heat-inactivated rabbit plasma to block nonspecific binding. Slides were then incubated with chicken anti-bovine LPL antibody (1:400 dilution) overnight. After being washed with TBS, slides were incubated with biotinylated rabbit anti-chicken IgG (1:150 dilution; Chemicon) and streptavidin-conjugated Cy3 fluorescent probe (1: 1,000 dilution) for 1 h. Slides were visualized using a Bio-Rad Confocal Microscope.
Treatments. Adenine 9-␤-D-arabinofuranoside (Ara-A), a precursor of Ara-ATP, is a competitive inhibitor of AMPK. Insulin is also known to inhibit AMPK phosphorylation. Thus fasted hearts were perfused for 1 h with Ara-A or insulin, and AMPK phosphorylation and heparin-releasable LPL activity were measured. To determine whether promotion of AMPK phosphorylation can influence cardiac LPL, isolated control hearts were perfused with perhexiline (1-10 M), both in the presence or absence of glucose for 45 min, and cardiac LPL activity was subsequently measured. Perhexiline, an anti-anginal agent, has been described to inhibit CPT-1 and myocardial consumption of FA, and in preliminary experiments, in the absence of glucose, has been shown to activate the phosphorylation of AMPK. To deplete intracellular ATP and induce metabolic stress and activation of AMPK, oligomycin (1-5 M), an inhibitor of the mitochondrial electron transport chain, was perfused through control hearts for 8 -30 min, and heparin-releasable cardiac LPL activity was subsequently measured. Oligomycin up to 300 M has been used previously in cardiomyocytes to activate AMPK (23) .
Serum measurements. Blood samples were removed from animals and centrifuged immediately to collect serum that was stored at Ϫ20°C until assayed. Diagnostic kits were used to measure glucose, TG (Sigma), and nonesterified fatty acid (Wako). On immediate removal of hearts from control and overnight-fasted rats, LPL activity was determined after perfusion with heparin. In a separate experiment, hearts from the two groups were first perfused for 1 h with Krebs buffer in the recirculating mode (and in the absence of heparin). During the 60-min perfusion, basal LPL activity was determined in the buffer reservoir over time (inset). Subsequently, LPL was displaced by heparin, and activity was determined. Results are means Ϯ SE of 4 rats in each group. B: representative photograph showing the effect of fasting on LPL immunofluorescence as visualized by fluorescent microscopy. Heart sections were fixed and incubated with the polyclonal chicken antibody against bovine LPL followed by incubations with biotinylated rabbit antichicken IgG and streptavidin-conjugated Cy3 fluorescent probe. *P Ͻ 0.05, significantly different from control.
Statistical analysis. Wherever appropriate, one-way ANOVA followed by the Tukey or Bonferroni tests or the unpaired and paired Student's t-test was used to determine differences between group mean values (as indicated in the legends for Figs. 1-7) . The level of statistical significance was set at P Ͻ 0.05.
Materials. Oligomycin, Ara-A, and perhexiline were purchased from Sigma. Total AMPK-␣ and phospho-AMPK-␣ antibodies were obtained from Cell Signaling (Beverly, MA). ECL detection kit was obtained from Amersham.
RESULTS

Fasting influences cardiac AMPK phosphorylation.
Previous studies have reported AMPK phosphorylation in the liver from fasted animals (43) . In the present study, overnight (16 h) fasting reduced serum glucose and TG levels, with no affect on free fatty acid (Table 1) . After fasting, an approximately threefold increase of AMPK phosphorylation was observed on immediate removal of the heart (Fig. 1) . Interestingly, perfusion with Krebs buffer for 1 h further augmented AMPK phosphorylation, but only in hearts from fasted animals (Fig. 1) .
Augmentation of heparin-releasable LPL persists in vitro in fasted hearts. AMPK is known to promote cardiac FA oxidation (37) . We considered whether the increase in AMPK phosphorylation is also related to increased FA delivery to the heart via LPL action at its functionally relevant location, the Fig. 3 . LPL gene expression, protein mass, and activity in hearts isolated from fasted animals. Rats were fasted for 16 h; during fasting, food was withdrawn from the animals, but they had free access to water. LPL gene expression in the whole heart was measured using RT-PCR (A). LPL protein (B) and activity (C) measurements were done using isolated cardiomyocytes. Data are means Ϯ SE of 3 different hearts in each group. Fig. 4 . Consequence of AMPK inhibition on heparin-releasable LPL activity in fasted hearts. AMPK phosphorylation in fasted hearts was inhibited using adenine 9-␤-D-arabinofuranoside (Ara-A, 500 M) or insulin (100 U/ml) perfusion for 1 h. Subsequently, LPL was displaced by heparin, and activity was determined (B), or total and phospho-AMPK-␣ were measured using Western blotting (A). Data are means Ϯ SE of 4 different hearts in each group. *P Ͻ 0.05, significantly different from control. coronary lumen. Results from this and a previous study (36) showed that overnight fasting for 16 h caused a 2.5-fold increase in LPL activity at the coronary lumen ( Fig. 2A, left) . Immunohistochemical studies of myocardial sections were performed to complement our observation that the augmented LPL in fasted hearts was mainly localized at the endothelial cells. Whereas LPL immunofluorescence was found throughout the control and fasted myocardium, capillary blood vessels in the fasted heart demonstrated a more intense LPL immunoreactivity compared with control (Fig. 2B) . Overall, our data suggest a correlation between AMPK phosphorylation and amplified endothelial LPL in fasted hearts.
To determine whether this increase in LPL is a consequence of changes in gene expression, LPL mRNA was measured. Interestingly, changes in luminal LPL activity were independent of shifts in mRNA levels (Fig. 3A) . Additionally, given that after fasting LPL protein (Fig. 3B) and activity (Fig. 3C) remain unchanged in cardiomyocytes, the predominant cell type in the heart responsible for LPL synthesis and processing, our data suggest that LPL increase at the coronary lumen is likely via posttranslational mechanisms.
Given that AMPK phosphorylation increased further in fasted hearts perfused for 1 h, we evaluated whether there would be an additional increase or maintenance of LPL over this period in vitro. Thus hearts from control and fasted animals were perfused with normal Krebs buffer (minus heparin) for 1 h followed by heparin perfusion for 10 min. Interestingly, after the 1-h perfusion, fasted hearts demonstrated no further increase in LPL activity ( Fig. 2A, right) . The ability of these hearts to maintain their high heparin-releasable LPL in vitro suggested either an increased recruitment from myocytes or decreased displacement from the coronary lumen. To evaluate this further, during the 60-min perfusion with heparin-free buffer in the recirculating mode, LPL activity in the buffer reservoir (total volume 30 ml) was determined at various intervals. Interestingly, fasted hearts showed greater basal release of LPL throughout the perfusion (Fig. 2, inset) . Hearts from control animals were perfused either in the presence or absence of perhexiline (5 mM), with or without glucose, for 45 min. Subsequently, LPL was displaced by heparin, and activity was determined (B) or AMPK was measured using Western blotting (A). Data are means Ϯ SE of 4 different hearts in each group. *P Ͻ 0.05, significantly different from control. Fig. 6 . Effect of inhibiting ATP synthesis on AMPK phosphorylation and heparin-releasable LPL activity. Hearts from control animals were perfused either in the presence or absence of oligomycin (1-5 M) for 8 min. Subsequently, LPL was displaced by heparin, and activity was determined (B) or AMPK was measured using Western blotting (A). Data are means Ϯ SE of 4 different hearts in each group. *P Ͻ 0.05, significantly different from control.
Inhibition of AMPK phosphorylation lowers cardiac LPL.
Because in vitro hearts from fasted animals maintain an augmented AMPK phosphorylation and LPL activity, we hypothesized that inhibition of AMPK phosphorylation should decrease LPL activity. Ara-A, a precursor of Ara-ATP, is a competitive inhibitor of AMPK (27) . Perfusion of fasted hearts for 1 h with Ara-A decreased AMPK phosphorylation (Fig.  4A) , had no effect on the augmented basal enzyme release (1.6-fold higher than control at 60 min), but decreased heparinreleasable LPL activity (Fig. 4B) . Because insulin is also known to inhibit AMPK phosphorylation (18) , fasted hearts were perfused for 1 h with insulin. Similar to Ara-A, insulin reduced both AMPK phosphorylation (Fig. 4A ) and luminal LPL activity (Fig. 4B) .
Promotion of AMPK phosphorylation in isolated control hearts recruits LPL to the luminal surface. In the presence of glucose, perfusion of isolated control hearts with perhexiline did not change either AMPK phosphorylation (Fig. 5A ) or LPL activity (Fig. 5B) . However, removal of glucose from the perfusion buffer significantly augmented both AMPK phosphorylation and luminal LPL activity (Fig. 5, A and B) . With oligomycin, there was a rapid and concentration-dependent increase in both AMPK phosphorylation (Fig. 6A ) and coronary luminal LPL (Fig. 6B) . Both perhexiline and oligomycin were without effect on LPL mRNA, protein, and activity in cardiomyocytes (data not shown).
DISCUSSION
AMPK is the switch that activates pathways that produce ATP while turning off ATP-consuming processes (14, 26) . Thus, during fasting, when glucose supply is inadequate and its oxidation is compromised because of PDK4 overexpression (28, 40) , AMPK activity is augmented in the liver (37) . The present study, for the first time, demonstrates that fasting also increases cardiac AMPK phosphorylation. Because activation of AMPK is known to exaggerate FA utilization in the ischemic reperfused heart (19), our results suggest that a similar relationship between AMPK activity and FA oxidation must also exist after fasting. Indeed, rates of cardiac oleate oxidation do increase after fasting (45) .
Given the role of AMPK in regulating FA oxidation, it is conceivable that it could also influence FA delivery. Provision of FA to the heart involves 1) release from adipose tissue and transport to the heart (22), 2) breakdown of endogenous cardiac TG stores, 3) internalization of whole lipoproteins, and 4) hydrolysis of circulating TG-rich lipoproteins to FA by LPL positioned at the endothelial surface of the coronary lumen (7), and AMPK has been implicated in some of these processes. Thus activation of AMPK is known to augment FA uptake in the contracting isolated cardiomyocyte through the recruitment of FA transporters to the plasma membrane (23) . Moreover, although its role in cardiac TG lipolysis is unknown, at least in adipocytes, AMPK is suggested to mediate the lipolytic effect of adrenergic stimulation (44) . Given that LPL-mediated hydrolysis of lipoproteins was recently suggested to be the principal source of FA for cardiac utilization (2, 41), we examined its relationship to AMPK activity. In agreement with previous studies, we observed an increase of heparin-releasable LPL activity after overnight fasting, and immunostaining revealed that most of the LPL protein was located at the coronary lumen. Our data suggest that AMPK phosphorylation may play a role in increasing cardiac functional LPL. Because changes in luminal LPL activity were independent of shifts in LPL mRNA or alterations in protein and activity in cardiomyocytes, our data imply that this LPL increase at the coronary lumen is likely via posttranslational mechanisms. Other studies have also established that the fasting-induced changes in cardiac LPL activity are likely through posttranslational mechanisms After synthesis and processing of LPL in myocytes, the enzyme is either transported to lysosomes for degradation or delivered to cell-surface heparan sulfate proteoglycan (HSPG) binding sites. From here, LPL is transferred to similar binding sites on the luminal surface of endothelial cells. At this location, the enzyme hydrolyzes the triglyceride core of circulating lipoproteins to free fatty acids, which are then transported to the heart for ATP generation. During metabolic stress, AMPK-mediated recruitment of LPL to the coronary lumen could represent an immediate compensatory response by the heart to guarantee FA supply. One such mechanism by which AMPK does this is through increased secretion/transfer of LPL from the myocyte to the coronary lumen. Additionally, AMPK may potentially reduce intracellular lysosomal degradation.
that do not involve alterations in mRNA levels, protein synthesis, or specific activity of the protein (10) . Moreover, at least in adipose tissue, downregulation of LPL during fasting is also posttranslational and involves a shift from active to inactive forms of the lipase (5) .
To further examine this relationship, hearts from fasted animals were perfused with Krebs buffer for 1 h (in the absence of heparin), and heparin-releasable LPL activity was subsequently determined. After the 1-h perfusion, only fasted hearts showed further increase in AMPK phosphorylation. Given that the fasted heart prefers FA as an energy substrate for ATP generation, it is likely that this added effect on AMPK phosphorylation is the result of lack of albumin-bound FA and circulating lipoproteins in the perfusate. It should be noted that, even though AMPK phosphorylation increased with time in vitro, heparin-releasable LPL activity at the coronary lumen did not expand further. Because previous studies have demonstrated that the coronary lumen of the rat heart has a finite number of LPL-binding sites and that, under normal conditions, only a fraction of these binding sites are occupied by LPL (29) , our present data are indicative of a model that suggests that, once AMPK activation fills these sites (after overnight fasting) with the enzyme, no further increase of LPL is possible. Interestingly, throughout the 1-h perfusion, fasted hearts showed greater basal release of LPL. Given that this increased basal LPL release was not followed by a decline in heparin-releasable LPL activity, our data suggest that, in vitro, it is likely that the fasted heart has higher enzyme transfer from the myocyte to the coronary lumen.
After ischemia and reperfusion, cardiac AMPK activity is activated, an effect that is prevented by insulin (3). Additionally, in skeletal muscle, stimulation of AMPK by 5-aminoimidazole-4-carboxamide-1-␤-D-riboturanoside has been shown to be normalized by Ara-A (27) . In our study, these agents were effective in lowering AMPK phosphorylation in the fasted heart. More importantly, in these hearts, insulin and Ara-A also reduced the endothelial-bound LPL pool. Our data suggest that, in vitro, the fasted heart is able to maintain its high LPL activity through AMPK, and inhibition of AMPK phosphorylation can lower this high enzyme activity.
A more direct examination of the relationship between AMPK and LPL was realized using compounds that activate AMPK. One mechanism by which AMPK is stimulated includes modulation of intracellular AMP concentrations. It should be noted that, since the effect of AMP can be antagonized by high concentrations of ATP, a higher AMP-to-ATP ratio is more efficient in activating AMPK than a rise in AMP alone (13) . Another method that can induce AMPK activation is through inhibition of ATP production that in turn increases intracellular generation of AMP (12) . Perhexiline, a CPT-1 blocker that is widely used in the treatment of ischemia, inhibits FA oxidation and switches the heart to utilize glucose. Given that FA is a major substrate contributing ϳ70% ATP in heart, we predicted that perhexiline would activate AMPK through impaired ATP generation. However, perfusion of control hearts with perhexiline was without effect on cardiac AMPK or LPL activity, suggesting that metabolic switching to utilize glucose may be sufficient to prevent ATP depletion. To test this idea, glucose was removed from our perfusion media when using perhexiline. Interestingly, this adjustment increased AMPK phosphorylation and was able to recruit LPL to the endothelial cell. Oligomycin, an ATP synthase inhibitor, has been shown to markedly change the AMP-to-ATP ratio and AMPK activity in isolated perfused hearts (25) and cardiomyocytes (23) . In our study, oligomycin increased AMPK phosphorylation and heparin-releasable LPL activity in a dosedependent manner. Given the rapid (8 min) augmentation of LPL after oligomycin, and in the absence of any change in LPL mRNA or protein and activity in cardiomyocytes, our data suggest that the regulation of LPL by AMPK is likely through posttranslational mechanisms. One such mechanism could include an increase in secretion of LPL from the myocyte to the coronary lumen. In this regard, despite the high basal release of LPL to the medium from isolated fasted hearts, heparinreleasable LPL activity remained high, suggesting augmented LPL transfer from myocyte to coronary lumen. However, even though enzyme transfer may have increased, LPL protein and activity remain unchanged in myocytes from fasted animals, suggesting that reduced intracellular lysosomal degradation may also be occurring concomitantly. In adipocytes, stimulation of LPL secretion is known to reduce enzyme degradation (9, 42) . Additionally, ATP depletion in Chinese hamster ovary cells after incubation with 2-deoxy-D-glucose drastically reduces LPL degradation rate (4) . At present, the target for AMPK phosphorylation that controls LPL secretion and degradation is not known.
In summary, using fasting and modulators of AMPK, a strong correlation between this metabolic switch and cardiac LPL activity was established. Given the rapidity by which oligomycin duplicates the above relationship, our data suggest that, in addition to its direct role in promoting FA oxidation, increased AMPK recruitment of LPL from its major storage site, the cardiomyocyte, to the coronary lumen and decreased intracellular degradation could represent an immediate compensatory response by the heart to guarantee FA supply (Fig. 7 ).
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